BIO-key Regains Compliance with Nasdaq Listing Rules; Nasdaq Trading Resumes on Wednesday, July 8th
Rhea-AI Summary
BIO-key (Nasdaq: BKYI) announced that trading of its common stock will resume on the Nasdaq Capital Market at the market open on Wednesday, July 8, 2026. A Nasdaq Hearings Panel determined the company has regained compliance with continued listing standards, including minimum bid price and SEC filing requirements. BIO-key will be under a Discretionary Panel Monitor until July 6, 2027. Management highlights a growing base of recurring revenue, expanding interest in its biometric cybersecurity solutions, a solid financial position, and a streamlined cost structure, and expects significantly improved business results in 2026.
Positive
- Nasdaq Capital Market trading resumes on July 8, 2026
- Regained compliance with Nasdaq continued listing standards
- Compliance includes minimum bid price and SEC filing requirements
- One-year oversight period may support continued compliance focus
- Management cites growing recurring revenue and streamlined cost structure
Negative
- Subject to Discretionary Panel Monitor until July 6, 2027
News Market Reaction – BKYI
On the day this news was published, BKYI gained 43.35%, reflecting a significant positive market reaction. Argus tracked a peak move of +17.6% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $6.25M at that time. Trading volume was exceptionally heavy at 7.3x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 02 | Cybersecurity workshop | Positive | -8.9% | Showcased passwordless biometric IAM solutions at Amman banking cybersecurity workshop. |
| Jun 18 | Defense tech conference | Positive | -2.3% | Maxim Group fireside chat with outlook for 1H 2026 revenue growth and profitability. |
| Jun 10 | Nasdaq non-compliance notice | Negative | -2.8% | Nasdaq notice for delayed Form 10-Q filing and continued listing risk. |
| Jun 04 | Investor conference | Positive | -3.6% | RedChip conference presentation with expectations for higher 1H 2026 revenue and profitability. |
| Jun 02 | Security deployment | Positive | +6.7% | PortalGuard deployment at AOD Federal Credit Union via BlueAlly partnership. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent BIO-key news, including positive operational and conference updates, often saw muted-to-negative price reactions, with only occasional alignment on clearly positive commercial announcements.
Key Terms
minimum bid price financial
sec filing requirements regulatory
discretionary panel monitor regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLMDEL, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management and biometric authentication technologies, today announced that The Nasdaq Stock Market LLC has notified it that the trading of its common stock will recommence on the Nasdaq Capital Market effective with markets’ opening on Wednesday, July 8, 2026.
Trading of BIO-key’s shares was restored following a June 16th hearing with a Nasdaq Hearings Panel, in which the Panel determined the Company has regained compliance with the continued listing standards, including minimum bid price and SEC filing requirements. The Company will be subject to a Discretionary Panel Monitor pursuant to Nasdaq Rule 5815(d)(4)(B) for a period of one year until July 6, 2027.
BIO-key CEO Michael DePasquale commented, “We are grateful to Nasdaq and the Hearings Panel for working with us through this process to successfully restore our shares to Nasdaq trading. We have built a growing base of recurring revenue, expanding interest in our biometric technology’s ability to solve pervasive cybersecurity vulnerabilities, a solid financial position, and a streamlined cost structure. It is an exciting moment for BIO-key as we expect our business to deliver significantly improved results this year.
About BIO-key International, Inc. (www.BIO-key.com)
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software that secures access for over forty million users worldwide. BIO-key enables customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its cloud-hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value data and transactions.
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements, whether as a result of new information, future events, or otherwise.
| Engage with BIO-key Corporate: | ||
| Facebook: | https://www.facebook.com/BIOkeyInternational/ | |
| LinkedIn: | https://www.linkedin.com/company/bio-key-international | |
| X: | @BIOkeyIntl | |
| Investors: | ||
| X: | @BIO_keyIR | |
| StockTwits: | @BIO_keyIR | |
Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com or 212-924-9800
